Emory University has discovered and advanced the development of some of the world’s most important and valuable antiviral drugs, successfully taking treatments from bench to bedside.
As one of the nation’s leading research universities, a key mission for Emory is to improve lives and provide hope to everyone we serve in all facets of our work. The criteria by which we measure our success include but are not limited to the lives saved, partnerships forged, solutions provided to real-world issues, and the scientific discoveries and foundation developed that will improve the health, wellness and safety of individuals around the globe for generations to come.
Molnupiravir was invented at Emory University. Drug Innovation Ventures at Emory (DRIVE) LLC, which was formed by Emory to develop early-stage drug candidates for viral diseases of global concern, advanced molnupiravir through an Investigational New Drug submission.
On Dec. 23, the U.S. Food and Drug Administration (FDA) announced that molnupiravir has received Emergency Use Authorization (EUA) for treatment of COVID-19.
The EUA authorizes the use of molnupiravir for “the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.”
For more information, visit the Drug Discovery at Emory website.
Gana Ahn
404-727-0343
gana.ahn@emory.edu
On Dec. 23, molnupiravir, an investigational oral antiviral drug invented by scientists at Emory University, received Emergency Use Authorization from the FDA for the treatment of COVID-19.
A FDA panel voted in favor of a proposed Emergency Use Authorization for the antiviral drug molnupiravir.
An Emory-invented antiviral treatment for COVID-19 has been authorized by British regulators, making molnupiravir the first antiviral pill approved for use against SARS-CoV-2. An emergency use application is also under consideration by the U.S. Food and Drug Administration.
The Medicines Patent Pool and Merck have entered into a licensing agreement to facilitate affordable access for molnupiravir, an investigational oral antiviral COVID-19 medicine, in 105 low- and middle-income countries.
With Merck’s findings that Emory-discovered molnupiravir may significantly reduce the risk of hospitalization or death from COVID-19, Emory President Gregory L. Fenves joins epidemiologist Jodie Guest in a conversation about Emory’s history of research innovation.
Molnupiravir, an investigational oral antiviral drug discovered by Emory researchers, appears to significantly reduce the risk of hospitalization or death in patients with mild to moderate COVID-19, according to interim data from a Phase 3 study.
Scientists are hopeful that a new drug discovered by researchers at Emory could change the way doctors treat COVID-19. The drug, called EIDD-2801, shows promise in reducing lung damage and has finished testing in mice. It will soon move to human clinical trials.
An antiviral drug initially discovered by Emory’s non-profit drug development company DRIVE appears safe and reduces SARS-CoV-2 to undetectable levels in COVID-19 patients after five days of administration, according to data from a Phase II clinical trial.
Scientists at the Max Planck Institute for Biophysical Chemistry in Germany have generated a structure showing how the antiviral drug molnupiravir drug works.
To address the intensifying COVID-19 crisis in India, the pharmaceutical company Merck has agreed to facilitate the manufacture and distribution of molnupiravir, an investigational antiviral drug that was discovered at Emory.
George Painter is a professor in the Department of Pharmacology and Chemical Biology at the Emory University School of Medicine, director of the Emory Institute for Drug Development and CEO of Drug Innovation Ventures at Emory (DRIVE).
